Given the role of EZH2 in modulating myogenic differentiation and promoting carcinogenesis, targeting EZH2 has emerged as a promising strategy in RMS treatment and in broader cancer therapy, potentially offering a new avenue to combat drug resistance and tumor recurrence [55]. This evidence concerns the gene EZH2 and cancer.